Athenex, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Yiu-Nam Lau F.R.C.P.,
- Full Time Employees
- 269
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Conventus Building Buffalo NY United States of America 14203
- IPO Date
- Jun 14, 2017
- CIK
- 0001300699
- Website
- athenex.com
- Similar Companies
- Business
- Athenex, Inc. Athenex, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for cancer treatment; it operates through the Oncology Innovation Platform, which advances drug candidates including Orascovery technology such as oral paclitaxel and encequidar for metastatic breast cancer, Src kinase inhibitors like tirbanibulin ointment for actinic keratosis, skin cancers, and psoriasis, and cell therapy programs featuring KUR-501 (autologous NKT cells for relapsed-refractory high-risk neuroblastoma), KUR-502 (allogeneic for CD19-positive malignancies), and KUR-503 (for hepatocellular carcinoma); and the Commercial Platform, which handles sales and marketing of specialty pharmaceuticals. The company maintains manufacturing and supply chain operations across North America and China, targeting oncology patients and healthcare providers globally with products derived from P-glycoprotein pump inhibitors, T-cell receptor-engineered therapies, and arginine deprivation technology. Founded in 2003 and headquartered in Buffalo, New York, Athenex formerly operated as Kinex Pharmaceuticals LLC until renaming in 2015. In May 2023, Athenex filed for voluntary Chapter 11 bankruptcy proceedings in the U.S. Bankruptcy Court for the Southern District of Texas to facilitate an expedited asset sale process across its pharmaceutical division, Orascovery, and cell therapy assets, with the plan approved for liquidation by September 2023; this followed regulatory setbacks including a complete response letter for oral paclitaxel, debt reduction efforts totaling $108 million, and strategic refocusing on NKT cell therapies amid challenging market conditions. Post-bankruptcy, the company engages in winding down operations, claim resolutions, and limited ongoing activities such as fulfilling prior customer orders through its pharma solutions arm, while its stock trades over-the-counter as ATNXQ.
Why Is Athenex (ATNX) Stock Down 54% Today?
Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process
Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCO
Athenex (ATNX) Upgraded to Buy: Here's Why
Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update
Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce Launch of a Generic Version of Magnesium Sulfate in Water for Injection, in Non-PVC, Single-Patient Use Containers by Their Partner Athenex Pharmaceutical Division (APD)
Athenex Announces a Reverse Stock Split
A Short Guide to Making Money With Penny Stocks in 2023
Penny Stocks To Buy? 3 Stocks Under $1 To Watch Now
Best Penny Stocks To Buy? 10 Under $1 To Watch This Week
Best Penny Stocks To Buy? 6 Under $1 To Watch Now
3 Hot Penny Stocks Under $1 To Watch This Week
3 Tips for Identifying Penny Stocks With High Potential
Why Is Athenex (ATNX) Stock Up 44% Today?
Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer
Athenex Exits 503B Sterile Compounding Business
Athenex Announces Positive Results of Special Stockholder Meeting
Athenex Announces Closing of the Sale of its China API Business
Athenex, Inc. (ATNX) CEO Johnson Lau on Q3 2022 Results - Earnings Call Transcript
Athenex (ATNX) Reports Q3 Loss, Tops Revenue Estimates